Sign up to access all valuation multiples
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
2015
23
Last FY Revenue $1.0M
Last FY EBITDA -$22.5M
$55.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the same period, vTv Therapeutics achieved -$30.7M in LTM net income.
See vTv Therapeutics valuation multiples based on analyst estimatesIn the most recent fiscal year, vTv Therapeutics reported revenue of $1.0M and EBITDA of -$22.5M.
vTv Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See vTv Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$22.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2214% | XXX | XXX | XXX |
| EBIT | -$35.5M | XXX | -$24.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -2378% | XXX | XXX | XXX |
| Net Profit | -$30.7M | XXX | -$18.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -1815% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
vTv Therapeutics has current market cap of $154M, and EV of $55.4M.
As of January 1, 2026, vTv Therapeutics's stock price is $39.
See vTv Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55.4M | $154M | XXX | XXX | XXX | XXX | $-4.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialvTv Therapeutics's trades at 54.4x EV/Revenue multiple, and -2.5x EV/EBITDA.
See valuation multiples for vTv Therapeutics and 15K+ public compsAs of January 1, 2026, vTv Therapeutics has market cap of $154M and EV of $55.4M.
Equity research analysts estimate vTv Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
vTv Therapeutics has a P/E ratio of -5.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $154M | XXX | $154M | XXX | XXX | XXX |
| EV (current) | $55.4M | XXX | $55.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 54.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.5x | XXX | XXX | XXX |
| EV/EBIT | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.0x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialvTv Therapeutics's revenue per employee in the last FY averaged $44K, while opex per employee averaged $1.1M for the same period.
vTv Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
vTv Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for vTv Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1135% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2478% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
vTv Therapeutics acquired XXX companies to date.
Last acquisition by vTv Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . vTv Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was vTv Therapeutics founded? | vTv Therapeutics was founded in 2015. |
| Where is vTv Therapeutics headquartered? | vTv Therapeutics is headquartered in United States of America. |
| How many employees does vTv Therapeutics have? | As of today, vTv Therapeutics has 23 employees. |
| Who is the CEO of vTv Therapeutics? | vTv Therapeutics's CEO is Mr. Paul J. Sekhri. |
| Is vTv Therapeutics publicy listed? | Yes, vTv Therapeutics is a public company listed on NAS. |
| What is the stock symbol of vTv Therapeutics? | vTv Therapeutics trades under VTVT ticker. |
| When did vTv Therapeutics go public? | vTv Therapeutics went public in 2015. |
| Who are competitors of vTv Therapeutics? | Similar companies to vTv Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of vTv Therapeutics? | vTv Therapeutics's current market cap is $154M |
| Is vTv Therapeutics profitable? | Yes, vTv Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of vTv Therapeutics? | vTv Therapeutics's last 12 months FCF is -$37.2M. |
| What is the current EV/FCF multiple of vTv Therapeutics? | Current FCF multiple of vTv Therapeutics is -1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
